… dose-limiting in this small sample of nonhospitalized adults with Covid-19. The … molnupiravir,
when initiated early in the course of illness, is an effective option for the treatment of adults …

… of treatment with molnupiravir started within 5 days after the onset of signs or symptoms in
nonhospitalized, unvaccinated adults … to receive 800 mg of molnupiravir or placebo twice daily …

… non-hospitalized adults and assessed treatment initiation with nirmatrelvir/ritonavir or
molnupiravir versus no antiviral treat… and/or molnupiravir were the intervention with the treatment …

… , is being repurposed for the treatment of COVID-19. This study evaluates the efficacy
and … of molnupiravir in addition to the standard-of-care (SOC) for the treatment of non-hospitalized …

… These findings support the recommended use of molnupiravir for treating nonhospitalized
… and November 2021 Nonhospitalized adults with COVID-19 within 5 days of symptom onset …

… significantly reduced the risk of hospitalization or death in adults … of molnupiravir given
within five days after the onset of signs or symptoms in unvaccinated and non-hospitalized adults …

… theoretical concerns that molnupiravir may cause mutations in … Authorization for molnupiravir
for treatment of adults with mild … Molnupiravir is not recommended during pregnancy and is …

… had no benefit for hospitalized patients and showed a decreased mortality risk for non-hospitalized
patients when compared to placebo [32]. This brief meta-analysis included two …

… including molnupiravir and nirmatrelvir plus ritonavir are novel options for treating adults …
with COVID-19 received molnupiravir or nirmatrelvir plus ritonavir treatment in the outpatient …

… early use of molnupiravir (Lagevrio) before marketing authorization, under Article 5(3) of
Regulation 726/2004. Molnupiravir can be used for the treatment of COVID-19 in adults who do …